JP2009529553A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529553A5
JP2009529553A5 JP2008558710A JP2008558710A JP2009529553A5 JP 2009529553 A5 JP2009529553 A5 JP 2009529553A5 JP 2008558710 A JP2008558710 A JP 2008558710A JP 2008558710 A JP2008558710 A JP 2008558710A JP 2009529553 A5 JP2009529553 A5 JP 2009529553A5
Authority
JP
Japan
Prior art keywords
phe
cys
glu
gly
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008558710A
Other languages
English (en)
Japanese (ja)
Other versions
JP5337493B2 (ja
JP2009529553A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/002216 external-priority patent/WO2007104541A2/en
Publication of JP2009529553A publication Critical patent/JP2009529553A/ja
Publication of JP2009529553A5 publication Critical patent/JP2009529553A5/ja
Application granted granted Critical
Publication of JP5337493B2 publication Critical patent/JP5337493B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008558710A 2006-03-16 2007-03-13 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法 Active JP5337493B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06360008.4 2006-03-16
EP06360008 2006-03-16
EP06291516 2006-09-26
EP06291516.0 2006-09-26
PCT/EP2007/002216 WO2007104541A2 (en) 2006-03-16 2007-03-13 Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012171140A Division JP2012211194A (ja) 2006-03-16 2012-08-01 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2009529553A JP2009529553A (ja) 2009-08-20
JP2009529553A5 true JP2009529553A5 (enExample) 2011-03-10
JP5337493B2 JP5337493B2 (ja) 2013-11-06

Family

ID=38292592

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008558710A Active JP5337493B2 (ja) 2006-03-16 2007-03-13 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法
JP2012171140A Withdrawn JP2012211194A (ja) 2006-03-16 2012-08-01 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012171140A Withdrawn JP2012211194A (ja) 2006-03-16 2012-08-01 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法

Country Status (12)

Country Link
US (3) US20070270344A1 (enExample)
JP (2) JP5337493B2 (enExample)
AU (1) AU2007224643B2 (enExample)
CA (1) CA2646285C (enExample)
DK (1) DK1854477T3 (enExample)
ES (2) ES2601554T3 (enExample)
HU (2) HUE031701T2 (enExample)
LT (2) LT2374472T (enExample)
PL (1) PL1854477T3 (enExample)
PT (2) PT2374472T (enExample)
SI (1) SI2374472T1 (enExample)
WO (1) WO2007104541A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
CA3050564A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006091459A2 (en) * 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
US7745587B2 (en) 2005-12-30 2010-06-29 Dyax Corp. Antibodies that bind MMP-14
DK1854477T3 (en) * 2006-03-16 2016-11-28 Dyax Corp Peptide inhibitors of plasma kallikrein for use in the treatment of eye disorders
WO2008091692A2 (en) * 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Methods of diagnosing, treating, and preventing increased vascular permeability
CA2707637A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
WO2010048432A1 (en) * 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
JP2016513682A (ja) 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
WO2015063465A2 (en) 2013-10-28 2015-05-07 Bicycle Therapeutics Limited Novel polypeptides
ES3065185T3 (en) 2014-01-21 2026-05-04 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
IL247942B (en) * 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
EP3376939B1 (en) * 2015-11-18 2022-05-11 University Of Louisville Research Foundation, Inc. Automated methods for the objective quantification of retinal characteristics by retinal region and diagnosis of retinal pathology
RU2622031C1 (ru) * 2015-12-07 2017-06-08 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения РФ Способ комбинированного лечения макулярного отека сетчатки
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
GB201522441D0 (en) * 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
ES3072908T3 (en) 2019-04-08 2026-07-06 Biocryst Pharm Inc Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
LT6899B (lt) * 2020-08-27 2022-04-11 Valstybinis mokslinių tyrimų institutas Fizinių ir technologijos mokslų centras Vario paviršiaus cheminio nikeliavimo būdas, nenaudojant aktyvavimo paladžiu
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
EP0737207B1 (en) * 1994-01-11 2004-09-22 Dyax Corporation Inhibitors of human plasmin derived from the kunitz domains
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CA2180950C (en) * 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
DE10060653A1 (de) * 2000-12-06 2002-06-20 Epcos Ag Elektrischer Doppelschicht-Kondensator
US20060122374A1 (en) 2002-02-07 2006-06-08 Peter Mertins Albumin-fused anti-angiogenesis peptides
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
PT2298278E (pt) * 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2004019968A1 (en) 2002-08-28 2004-03-11 Dyax Corp. Methods for preserving organs and tissues
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
CA3050564A1 (en) 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
CA2537113A1 (en) 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
US7276480B1 (en) * 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US20070213275A1 (en) * 2006-03-10 2007-09-13 Dyax Corp. Formulations for ecallantide
DK1854477T3 (en) 2006-03-16 2016-11-28 Dyax Corp Peptide inhibitors of plasma kallikrein for use in the treatment of eye disorders
US8467792B2 (en) * 2006-06-27 2013-06-18 Qualcomm Incorporated Method and apparatus for maintaining call continuity in wireless communication
WO2009026334A2 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2009026539A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2010048432A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders

Similar Documents

Publication Publication Date Title
JP2005534647A5 (enExample)
JP2008514624A5 (enExample)
CA2320371A1 (en) Inotropic and diuretic effects of exendin and glp-1
ES2297902T5 (es) Compuestos novedosos agonistas de exendina
MX2009006348A (es) Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion.
ES2514615T3 (es) Proteínas de dominio Kunitz inhibidores de calicreína y ácidos nucleicos que codifican las mismas
ES2682646T3 (es) Composiciones y métodos para el tratamiento de trastornos oftálmicos
JP2008500281A5 (enExample)
de Rougemont et al. Preconditioning, organ preservation, and postconditioning to prevent ischemia‐reperfusion injury to the liver
White et al. A cardioprotective preservation strategy employing ex vivo heart perfusion facilitates successful transplant of donor hearts after cardiocirculatory death
Vinten-Johansen et al. Inflammation, proinflammatory mediators and myocardial ischemia–reperfusion Injury
US10300029B2 (en) Organ protection solutions and method of use
Schlegel et al. Hypothermic machine perfusion in liver transplantation
JP5705324B2 (ja) 灌流組成物
US20060069020A1 (en) Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
PE20030820A1 (es) Analogos extendidos de peptido 1 de tipo glucagon
EP2386310A2 (en) Methods for preserving organs and tissues
UA102370C2 (ru) Пептид, фармацевтическая композиция и лекарственное средство, которое его содержит, способ лечения и/или предупреждения диабета и сопутствующих ожирению заболеваний, способ снижения аппетита, снижение поглощения пищи и снижение массы тела
JP2020500163A5 (enExample)
GB2640988A (en) Amylin analogues
CN107105640A (zh) 具有控制的钙离子水平的新型组合物和溶液以及用于再灌注的相关方法和用途
DK1506225T4 (da) Hidtil ukendte peptidsammensætninger og anvendelse deraf i fremstillingen af aktive farmaceutiske sammensætninger mod hepatitis c-virus
WO2020026227A1 (en) Methods and uses of alpha 1-antitrypsin for preservation of explanted organs
Stowe et al. Reperfusion with adenosine and nitroprusside improves preservation of isolated guinea pig hearts after 22 hours of cold perfusion with 2, 3 butanedione monoxime
Shinohara et al. Ischemic postconditioning promotes left ventricular functional recovery after cardioplegic arrest in an in vivo piglet model of global ischemia reperfusion injury on cardiopulmonary bypass